
## Lucie Roussel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/170068/publications.pdf Version: 2024-02-01



LUCIE POUSSEL

#	Article	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,983
2	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,749
3	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	5.6	357
4	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	3.3	110
5	Loss of human ICOSL results in combined immunodeficiency. Journal of Experimental Medicine, 2018, 215, 3151-3164.	4.2	40
6	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology, 2023, 8, .	5.6	35
7	ICOSL in host defense at epithelial barriers: lessons from ICOSLG deficiency. Current Opinion in Immunology, 2021, 72, 21-26.	2.4	12
8	Differential Contribution of the Aryl-Hydrocarbon Receptor and Toll-Like Receptor Pathways to IL-8 Expression in Normal and Cystic Fibrosis Airway Epithelial Cells Exposed to Pseudomonas aeruginosa. Frontiers in Cell and Developmental Biology, 2016, 4, 148.	1.8	9
9	Fecal host biomarkers predicting severity of Clostridioides difficile infection. JCI Insight, 2021, 6, .	2.3	4
10	Decreasing SMPD1 activity in BEAS-2B bronchial airway epithelial cells results in increased NRF2 activity, cytokine synthesis and neutrophil recruitment. Biochemical and Biophysical Research Communications, 2017, 482, 645-650.	1.0	3
11	Late-Onset Combined Immunodeficiency with Refractory CMV Disease due to ICOSL Deficiency. Journal of Clinical Immunology, 2021, , 1.	2.0	1